Skip to main content
Clinical Trials/NCT01437579
NCT01437579
Unknown
Phase 2

Randomized Controlled Trial for Efficacy of Botulinum Toxin Type A in Treatment of Patients Suffering Bladder Pain Syndrome/Interstitial Cystitis With Hunners' Lesions

Moscow State University of Medicine and Dentistry1 site in 1 country60 target enrollmentJune 2011

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Interstitial Cystitis
Sponsor
Moscow State University of Medicine and Dentistry
Enrollment
60
Locations
1
Primary Endpoint
Change from baseline in pain intensity
Last Updated
14 years ago

Overview

Brief Summary

The etiology of bladder pain syndrome is unknown. Therefore the management is directed to pain relief, as bladder pain is believed to drive both voiding frequency and nocturia. Botulinum toxin A has been shown to decrease noxious input. Several studies showed efficacy of botox for treatment of painful bladder.

The aim of this study is to evaluate the efficacy of Botulinum toxin in patients who are suffering bladder pain syndrome with Hunner lesions during cystoscopy.

Registry
clinicaltrials.gov
Start Date
June 2011
End Date
June 2012
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Moscow State University of Medicine and Dentistry
Responsible Party
Principal Investigator
Principal Investigator

George Kasyan

Assistant Professor

Moscow State University of Medicine and Dentistry

Eligibility Criteria

Inclusion Criteria

  • longer than 6 months of bladder pain syndrome/interstitial cystitis with Hunner Lesion(s) during cystoscopy

Exclusion Criteria

  • Pregnancy
  • neurologic diseases
  • urinary tract infections
  • bladder outlet obstruction
  • previous pelvic radiotherapy

Outcomes

Primary Outcomes

Change from baseline in pain intensity

Time Frame: 1 week followed by 1, 3, and 6 months after BoNTA injection

Pain intensity is scored using a 10-point visual analog scale and change from baseline is observed

Change from baseline of intensity of bladder bother symptoms

Time Frame: within 1 week, at 3 months and 6 months

O'Leary-Sant score was used to assess symptoms and problems.

Change from baseline of quality of life

Time Frame: within 1 week, at 3 months and 6 months

Quality of life (QoL) was evaluated using question 8 of the International Prostate Symptoms Score.

Secondary Outcomes

  • Postvoid residual urine volume(within 1 week, at 3months and 6 months after BoNTA injection)
  • Upper urinary tract retention(1 week, 3 months and 6 months after BoNTA injection)

Study Sites (1)

Loading locations...

Similar Trials